ArticlePolymers2022
Evaluation of Strong Cation Ion-Exchange Resin Cost Efficiency in Manufacturing Applications-A Case Study.
Article in Polymers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The effective ionic capacities of strong cation ion-exchange resins were investigated and compared using conditions similar to those found in white goods, in order to establish behavioral differences between commercial products and evaluate their capacity in a broader business context. Nine different products of equivalent TDS (Technical Data Sheet) capacity were observed to examine their differences in approximately real-life conditions. For a broader context of applicability analysis, besides the absolute ionic operating capacity, the following additional factors were included in the evaluation: the standard deviation in the resins' performances and their relative prices. A complete method for material applicability evaluation was hereby proposed and shown to offer cost factor benefits of up to 21.1% within the range of products examined, in comparison to a cost-only evaluation for equivalent materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.